Therapeutic Drug Monitoring of Voriconazole After Intravenous Administration in Infants and Children With Primary Immunodeficiency.

摘要

OBJECTIVE:: A voriconazole trough concentration (Ctrough) <1 mg/L is associated with a higher risk of treatment failure. The aim of this work was to describe the probability of not achieving this target concentration in infants and children receiving intravenous voriconazole. METHODS:: Voriconazole trough concentrations obtained during routine therapeutic drug monitoring over a 5-year period were collected retrospectively from infants and children receiving intravenous voriconazole for presumed or proven invasive fungal infections. RESULTS:: Sixty-two trough concentrations were obtained from 6 infants and 10 children. The risk of a Ctrough <1 mg/L was 77% and 47%, respectively. Daily doses between 20 and 32 mg/kg were necessary in some patients to achieve a Ctrough >1 mg/L, compared with the currently recommended 14-mg/kg regimen. CONCLUSIONS:: Routine therapeutic drug monitoring is potentially helpful in infants and children receiving voriconazole, even intravenously.